Elliott DM1, Singh N1, Nagarkatti M1, Nagarkatti PS1.Author information1Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.Abstract
Multiple sclerosis (MS) is a chronic debilitating autoimmune disease without a cure. While the use of marijuana cannabinoids for MS has recently been approved in some countries, the precise mechanism of action leading to attenuate neuroinflammation is not clear. We used experimental autoimmune encephalomyelitis (EAE), a murine model of MS, to explore the anti-inflammatory properties of cannabidiol (CBD), a non-psychoactive cannabinoid. Treatment with CBD caused attenuation of EAE disease paradigms as indicated by a significant reduction in clinical scores of paralysis, decreased T cell infiltration in the central nervous system, and reduced levels of IL-17 and IFNγ. Interestingly, CBD treatment led to a profound increase in myeloid-derived suppressor cells (MDSCs) in EAE mice when compared to the vehicle-treated EAE controls. These MDSCs caused robust inhibition of MOG-induced proliferation of T cells in vitro. Moreover, adoptive transfer of CBD-induced MDSCs ameliorated EAE while MDSC depletion reversed the beneficial effects of CBD treatment, thereby conclusively demonstrating that MDSCs played a crucial role in CBD-mediated attenuation of EAE. Together, these studies demonstrate for the first time that CBD treatment may ameliorate EAE through induction of immunosuppressive MDSCs.
autoimmunity; cannabidiol; experimental autoimmune encephalomyelitis; inflammation; marijuana; microRNA; multiple sclerosis; myeloid-derived suppressor cells
PMID: 30123217 PMCID: PMC6085417 DOI: 10.3389/fimmu.2018.01782 Free PMC ArticleShareImages from this publication.See all images (6)Free text
View the Original article